Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Peterson

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Plos One|January 11, 2018
Developmental finite element analysis of cichlid pharyngeal jaws: Quantifying the generation of a key innovationTim Peterson, Gerd B Müller
Journal of Experimental Zoology. Part B, Molecular and Developmental Evolution|June 25, 2013
What is evolutionary novelty? Process versus character based definitionsTim Peterson, Gerd B Müller
Evolutionary Biology|August 12, 2016
Phenotypic Novelty in EvoDevo: The Distinction Between Continuous and Discontinuous Variation and Its Importance in Evolutionary TheoryTim Peterson, Gerd B Müller
BMC Health Services Research|November 2, 2023
Conceptualizing lifer versus destination patients for optimized care deliveryJacob Lambrecht, Mahshid Abir, Kristian Seiler, et al.
British Journal of Haematology|August 16, 2021
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxisKatrina Piedra, Tim Peterson, Carlyn Tan, et al.
Nature Communications|November 26, 2025
Very long-chain fatty acids drive 1-deoxySphingolipid toxicityAdam Majcher, Gergely Karsai, Elkhan Yusifov, et al.
Neuro-Oncology|September 28, 2015
Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profilingJulia V Cockle, Karishma Rajani, Shane Zaidi, et al.
Bone Marrow Transplantation|June 17, 2020
COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasmaAlex Niu, April McDougal, Bo Ning, et al.
Cancer Research|November 20, 2002
Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cellsAndrew R Bateman, Kevin J Harrington, Tim Kottke, et al.
The Lancet. Haematology|May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Plos One|January 11, 2018
Developmental finite element analysis of cichlid pharyngeal jaws: Quantifying the generation of a key innovationTim Peterson, Gerd B Müller
Journal of Experimental Zoology. Part B, Molecular and Developmental Evolution|June 25, 2013
What is evolutionary novelty? Process versus character based definitionsTim Peterson, Gerd B Müller
Evolutionary Biology|August 12, 2016
Phenotypic Novelty in EvoDevo: The Distinction Between Continuous and Discontinuous Variation and Its Importance in Evolutionary TheoryTim Peterson, Gerd B Müller
BMC Health Services Research|November 2, 2023
Conceptualizing lifer versus destination patients for optimized care deliveryJacob Lambrecht, Mahshid Abir, Kristian Seiler, et al.
British Journal of Haematology|August 16, 2021
Comparison of venous thromboembolism incidence in newly diagnosed multiple myeloma patients receiving bortezomib, lenalidomide, dexamethasone (RVD) or carfilzomib, lenalidomide, dexamethasone (KRD) with aspirin or rivaroxaban thromboprophylaxisKatrina Piedra, Tim Peterson, Carlyn Tan, et al.
Nature Communications|November 26, 2025
Very long-chain fatty acids drive 1-deoxySphingolipid toxicityAdam Majcher, Gergely Karsai, Elkhan Yusifov, et al.
Neuro-Oncology|September 28, 2015
Combination viroimmunotherapy with checkpoint inhibition to treat glioma, based on location-specific tumor profilingJulia V Cockle, Karishma Rajani, Shane Zaidi, et al.
Bone Marrow Transplantation|June 17, 2020
COVID-19 in allogeneic stem cell transplant: high false-negative probability and role of CRISPR and convalescent plasmaAlex Niu, April McDougal, Bo Ning, et al.
Cancer Research|November 20, 2002
Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cellsAndrew R Bateman, Kevin J Harrington, Tim Kottke, et al.
The Lancet. Haematology|May 28, 2021
Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trialBenjamin Diamond, Neha Korde, Alexander M Lesokhin, et al.
Pageof 1